Benitec Biopharma Inc. (NasdaqCM: BNTC)
Health Care · Biotechnology · US
$9.15
+3.16% today · -40.5% 1Y
Benitec Biopharma Inc. (NasdaqCM: BNTC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $309.41M and employs 24 people.
Over the last twelve months the share price has lost 40.5%, trading between 8.52 and 16.76.
Tweenvest scores Benitec Biopharma Inc. across four factors: quality 39/100, value 74/100. Its strongest factor is value.
BNTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $309.41M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.98
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- $16.76
- 52-week low
- $8.52
- Avg volume (3M)
- —
- Shares outstanding
- 34.88M
- Employees
- 24
- Next earnings
- —
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
- ISIN
- US08205P2092
- Listed since
- Jun 24, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Circio Holding ASAOB: CRNA | $319.79M | Nkr11.04 | -0.90% |
| Cypherpunk Technologies Inc.NasdaqCM: CYPH | $316.83M | $2.92 | -0.68% |
| Medy-Tox Inc.KOSDAQ: A086900 | $316.58M | ₩65,900.00 | -1.05% |
| Orum Therapeutics, Inc.KOSDAQ: A475830 | $311.80M | ₩19,270.00 | -8.89% |
| TCM Biotech International Corp.TWSE: 4169 | $306.45M | NT$147.50 | -2.64% |
| Perspective Therapeutics, Inc.NYSEAM: CATX | $303.64M | $2.56 | -3.95% |
| AprilBio Co.,Ltd.KOSDAQ: A397030 | $297.93M | ₩14,560.00 | -14.45% |
| Curocell Inc.KOSDAQ: A372320 | $296.19M | ₩26,150.00 | +13.70% |
Figures last refreshed Oct 11, 2026.